Merck & Co., Inc. (LON:0QAH)

London flag London · Delayed Price · Currency is GBP · Price in USD
110.05
+0.46 (0.42%)
At close: Jan 30, 2026
11.61%
Market Cap199.50B -3.6%
Revenue (ttm)47.79B +1.7%
Net Income14.16B +56.7%
EPS5.62 +58.1%
Shares Outn/a
PE Ratio14.09
Forward PE21.70
Dividend2.45 (2.23%)
Ex-Dividend DateDec 15, 2025
Volume13,774
Average Volume17,771
Open108.00
Previous Close109.59
Day's Range106.50 - 110.27
52-Week Range70.15 - 112.36
Beta0.30
RSI58.33
Earnings DateFeb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange London Stock Exchange
Ticker Symbol 0QAH
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements